Arbutus Biopharma Corp (ABUS)
$4.19+1.95%Close
SELLCRISIS · day 6
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $828M
- Beta
- 0.62
- P/E (TTM)
- 5.30
- Short % float
- 21.67%
- Days to cover
- 3.5
- SI change
- +84.2%
- 1W
- -2.33%
- 1M
- -17.19%
- vs SPY 1W
- -1.35%
- vs SPY 1M
- -19.06%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS & VALIDATION
[SCORES & PROFILE]
- FUND
- 39
- VALUE
- 31
- GROWTH
- 73
- GARP
- 15
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC54.6%
REV YoY-
ROE91.0%
EPS YoY-
ROA55.9%
GROSS100
OP81
NET84
[VALUATION]
P/E TTM5.30
P/E FWD-
SECTOR PE20.48
INDUSTRY PE13.99
P/B3.20
P/FCF-
EV/EBITDA5.30
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E1.40
ALTMAN Z-
CURR RATIO81.42
ND/EBITDA-
BETA0.62
[BEST COMBO]VALIDATED · V5
ENTER · HOLD · EXIT · WAITOne next-open action from five signal families, published only when the held-out edge survives 20 bps costs.
Today's action with its out-of-fold profit factor, trade count and family votes.
[WHITE ARROW]FULL HISTORY
SELL
Directional consensus stays BUY or SELL until the model reverses; trades fill next session open.
PROFIT FACTOR2.0
TRADES89
[REGIME]FULL HISTORY
CRISIS
BULL or RECOVERY stays invested; BEAR or CRISIS exits at the next session open.
Profit factor and trade count for holding this symbol only in BULL or RECOVERY.
[EXHAUSTION]NOW
Whether buyers or sellers are stretched today, the latest release and its strength.
Company news
FAQ
- What is LOPJLB’s current signal on ABUS?
- LOPJLB’s latest quantitative signal on Arbutus Biopharma Corp (ABUS) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is ABUS in?
- Arbutus Biopharma Corp (ABUS) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Arbutus Biopharma Corp (ABUS) do?
- Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and…